European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)
The European urology guideline sets out how to diagnose, resect, risk-group and treat bladder cancers that have not reached the muscle, including when BCG is needed and when to remove the bladder.
Overview
Evidence-based guideline from the European Association of Urology covering diagnosis, transurethral resection, re-resection, risk stratification, intravesical chemotherapy and BCG, management of BCG failure, and follow-up for non-muscle-invasive bladder cancer.
It introduces the 2021 EAU risk groups with a very-high-risk category for which early radical cystectomy is recommended, and defines BCG-unresponsive disease for trial and treatment purposes.
Most of the decisions on a non-muscle-invasive bladder cancer page (single instillation, BCG maintenance, early cystectomy, bladder-sparing trials) follow this guideline or its American counterpart.
- Updated yearly; check the current edition for the latest recommendations on new bladder-sparing agents.